Literature DB >> 23178293

The TNF family member APRIL dampens collagen-induced arthritis.

Leticia Fernandez1, Gabriela Franco Salinas, Cecilia Rocha, Carla E Carvalho-Pinto, Nataliya Yeremenko, Laura Papon, Jan Paul Medema, Bernard Combe, Jacques Morel, Dominique Baeten, Michael Hahne.   

Abstract

BACKGROUND: The tumour necrosis factor (TNF)-family members B cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL) play important roles in B cell biology, and share binding to B cell maturation antigen and transmembrane activator and cyclophilin ligand interactor, both receptors of the TNF-family. However, while it is reported that BAFF can break B cell tolerance, the role of APRIL in autoimmunity remains elusive.
OBJECTIVE: To evaluate the role of APRIL on collagen-induced arthritis (CIA).
METHODS: CIA was induced in APRIL-transgenic (Tg) DBA/1 mice and littermates. Disease progression was evaluated by clinical and histological signs of arthritis. In another experimental setting mice were exposed to the collagen antibody-induced arthritis. In addition, we tested T cell dependent humoral responses in APRIL-Tg mice.
RESULTS: We found that APRIL-Tg displayed a strongly reduced incidence and severity of CIA compared with littermates, with decreases in collagen-specific autoantibody titres, immune complex deposition and downstream mast cell activation in joints. Notably, ectopic APRIL-expression was also found to negatively regulate T cell dependent humoral responses. The lower autoantibody production in APRIL-Tg mice during CIA appears to be crucial, as arthritis induced by administration of anti-collagen antibodies developed similar in APRIL-Tg and control mice, thus demonstrating that the downstream effector pathways induced by anti-collagen antibodies remain intact in APRIL-Tg mice. This protective effect was specifically mediated by APRIL, as adenoviral delivery of APRIL decreased CIA in a therapeutic setting.
CONCLUSIONS: Collectively, our data identify APRIL as a negative regulator of CIA by regulating autoantibody production. These findings are of important clinical relevance, as the therapeutic potential of transmembrane activator and cyclophilin ligand interactor-Fc (atacicept) is presently evaluated in clinical trials.

Entities:  

Keywords:  Arthritis; B cells; Cytokines

Mesh:

Substances:

Year:  2012        PMID: 23178293     DOI: 10.1136/annrheumdis-2012-202382

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  9 in total

1.  APRIL suppresses CIA in mice.

Authors:  Iley Ozerlat
Journal:  Nat Rev Rheumatol       Date:  2012-12-11       Impact factor: 20.543

Review 2.  Emerging immunotherapies for rheumatoid arthritis.

Authors:  Gary Reynolds; Faye A H Cooles; John D Isaacs; Catharien M U Hilkens
Journal:  Hum Vaccin Immunother       Date:  2014-02-17       Impact factor: 3.452

3.  To target or not to target APRIL in systemic lupus erythematosus: that is the question!

Authors:  Jacques Morel; Michael Hahne
Journal:  Arthritis Res Ther       Date:  2013-02-25       Impact factor: 5.156

4.  Decreased Circulating Levels of APRIL: Questioning Its Role in Diabetes.

Authors:  Adriana Carvalho-Santos; Marcelo Ribeiro-Alves; Luciene Carvalho Cardoso-Weide; Joyce Nunes; Lia Rafaella Ballard Kuhnert; Analucia Rampazzo Xavier; Samuel Cunha; Michael Hahne; Déa Maria Serra Villa-Verde; Carla Eponina Carvalho-Pinto
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

5.  Impact of the B Cell Growth Factor APRIL on the Qualitative and Immunological Characteristics of Atherosclerotic Plaques.

Authors:  Sophie J Bernelot Moens; Sander I van Leuven; Kang H Zheng; Stefan R Havik; Miranda V Versloot; Leonie M van Duivenvoorde; Michael Hahne; Erik S G Stroes; Dominique L Baeten; Anouk A J Hamers
Journal:  PLoS One       Date:  2016-11-07       Impact factor: 3.240

6.  APRIL Induces a Novel Subset of IgA+ Regulatory B Cells That Suppress Inflammation via Expression of IL-10 and PD-L1.

Authors:  Cynthia M Fehres; Nathalie O van Uden; Nataliya G Yeremenko; Leticia Fernandez; Gabriela Franco Salinas; Leonie M van Duivenvoorde; Bertrand Huard; Jacques Morel; Hergen Spits; Michael Hahne; Dominique L P Baeten
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

Review 7.  B-cell targeted therapeutics in clinical development.

Authors:  Stephan Blüml; Kathleen McKeever; Rachel Ettinger; Josef Smolen; Ronald Herbst
Journal:  Arthritis Res Ther       Date:  2013-04-04       Impact factor: 5.156

8.  Profiling of B-Cell Factors and Their Decoy Receptors in Rheumatoid Arthritis: Association With Clinical Features and Treatment Outcomes.

Authors:  Javier Rodríguez-Carrio; Mercedes Alperi-López; Patricia López; Francisco J Ballina-García; Ana Suárez
Journal:  Front Immunol       Date:  2018-10-11       Impact factor: 7.561

Review 9.  The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.

Authors:  Fabien B Vincent; Damien Saulep-Easton; William A Figgett; Kirsten A Fairfax; Fabienne Mackay
Journal:  Cytokine Growth Factor Rev       Date:  2013-05-15       Impact factor: 7.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.